supplementary figure 1lewis, et al

1
Supplementary Figure 1 Lewis, et al. a b Dacetuzumab (soluble) Dacetuzumab (crosslinked) 1 3 10 1 3 10 10 10 20 Untreated hIgG (soluble) hIgG (crosslinked) Crosslinking Ab CD40 Ligand g/ml phospho-AKT phospho-ERK1/2 MAPK IB- phospho-p38 MAPK Lane: 1 2 3 4 5 6 7 8 9 10 11 1 Untreated hIgG (crosslinked) Dacetuzumab (soluble) Dacetuzumab (crosslinked) Cell Death (Ramos) Percent Cell Death (apoptotic + necrotic) Dacetuzumab (crosslinked) Proliferation (Ramos) ng/ml Dacetuzumab Signaling (RL) phospho-ERK1/2 MAPK -Actin 1 11 ng/ml Dacetuzumab Untreated 33 3 1 .00x10 3 3 7.0 1 2.3 4 .12 Ramos c

Upload: elsu

Post on 27-Jan-2016

28 views

Category:

Documents


4 download

DESCRIPTION

Cell Death (Ramos). Untreated. Proliferation (Ramos). hIgG (crosslinked). Dacetuzumab (soluble). Dacetuzumab (crosslinked). Percent Cell Death (apoptotic + necrotic). Crosslinking Ab. Dacetuzumab (soluble). hIgG (crosslinked). Dacetuzumab (crosslinked). CD40 Ligand. - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Supplementary Figure 1Lewis,  et al

Supplementary Figure 1 Lewis, et al.

a

b

Da

ce

tuzu

ma

b

(s

olu

ble

)

Da

ce

tuzu

ma

b(c

ross

linke

d)

1 3 10 1 3 10 10 10 20

Un

tre

ate

d

hIg

G (

solu

ble

)

hIg

G (

cro

sslin

ked

)

Cro

ss

lin

kin

g A

bC

D4

0 L

iga

nd

g/ml

phospho-AKT

phospho-ERK1/2 MAPK

IB-

phospho-p38 MAPK

Lane: 1 2 3 4 5 6 7 8 9 10 11

1

Untreated

hIgG (crosslinked)

Dacetuzumab (soluble)

Dacetuzumab (crosslinked)

Cell Death (Ramos)

Pe

rce

nt

Ce

ll D

ea

th

(ap

op

toti

c +

nec

roti

c)

Dacetuzumab (crosslinked)

Proliferation (Ramos)

ng/ml

Dacetuzumab Signaling (RL)

phospho-ERK1/2 MAPK

-Actin

111

ng/ml

Dacetuzumab

Un

trea

ted

333

1.00

x10

3

37.0

12.3

4.12

Ramos

c